SOLVE
SOLVE - # 649 DelistedGobal Asset
-
Rating Score 38.38Rating Grade D
- Rating Version APYWA-v1.1 / Rating Date 2025-12-22
Overview
Solve.Care (SOLVE) is a blockchain-based platform designed for healthcare services and data management, enabling users to optimize access to medical services and reduce costs. Solve.Care aims to decentralize healthcare data management and deliver patient-centric, personalized services. The SOLVE token is used for a variety of purposes, including payment for services, data transactions, and participation in reward systems.
Metric Radar Chart
Metric Bar Chart
Metric Trends
| Total Rating Score | TNNeutral |
|---|---|
| Market Accessibility | TNNeutral |
| Development Activity | TNNeutral |
| Market Liquidity | TNNeutral |
| Community Engagement | TH2Gradual Uptrend |
| Risk & Security | TNNeutral |
Total Rating Score Trend
Market Data
- Token Price $0.000154 (↗0.65%)
- Volume (24h) $50 (↗2.04%)
- Market Cap $107.57K (↗2.13%)
-
Circulating Supply
700,125,013 SOLVE
850,000,000 SOLVE
(Source : Coinmarketcap , Coingecko )
Listed Exchanges
- Korean
-
- Global
×
View All Exchanges
- Korean
-
- Global
Community Info
X (Twitter) Tweets (Last 30 Days)
37 (-1)
Development Info
-
GitHub Account
SolveCare
-
Stars
60 (-)
- Commits (Last 3 Months) 0 (-)
Security Audit Info
- Security Audit Status None
- CertiK Code Security Score 63 pts
(Source : Coinmarketcap , CertiK Skynet )
Issue Info
- Trading History
- 2025.02.24 [업비트] 거래소에서 거래지원 종료되었습니다. 출금지원 종료 일정: 2025년 3월 26일(수)
- 2025.01.24 [업비트] 거래소에서 거래지원 종료 공지되었습니다. 거래지원 종료 일정: 2025년 02월 24일(월)
- 2025.01.10 [업비트] 거래소에서 유의종목 지정되었습니다.
- Risk History
- No records found
View Full History
| Category | Date | Exchange | Link | Grade | Details |
|---|---|---|---|---|---|
| Regular Evaluation | 2025-09-08 | - | - | D(39.01) | [AW-0089-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-04 | - | - | D(39.01) | [AW-0088-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-01 | - | - | D(39.46) | [AW-0087-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-28 | - | - | C-(40.81) | [AW-0086-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-25 | - | - | C-(41.26) | [AW-0085-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-21 | - | - | C-(42.25) | [AW-0084-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-18 | - | - | C-(42.25) | [AW-0083-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-14 | - | - | C-(42.34) | [AW-0082-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-11 | - | - | C-(42.25) | [AW-0081-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-08-07 | - | - | C-(42.34) | [AW-0080-정기] 평가가 완료되었습니다. |
- Disclaimer
-
The ratings provided by APYWA (hereinafter 'the Company') are conducted via an automated system based on public data and are pure data-driven analysis results with no subjective elements. This rating material includes evaluations on five key metrics: Market Accessibility, Development Activity, Market Liquidity, Community Engagement, and Security. All information provided is for reference purposes only.
Our ratings are not intended as investment advice or recommendations, and we do not guarantee the accuracy, completeness, or timeliness of the information. Users must make their own investment decisions based on the provided data, and the Company bears no legal liability for any resulting losses or damages.
While the rating material is processed automatically based on reliable data, discrepancies with actual market conditions may occur due to data limitations. Therefore, the Company is not liable for any damages arising from the use of the provided information. All information contained herein is the property of the Company and may not be reproduced, distributed, or modified without prior approval.